Bluejay Diagnostics, Inc. (BJDX): Price and Financial Metrics
BJDX Price/Volume Stats
| Current price | $0.64 | 52-week high | $13.98 |
| Prev. close | $0.55 | 52-week low | $0.47 |
| Day low | $0.57 | Volume | 739,700 |
| Day high | $0.67 | Avg. volume | 54,247 |
| 50-day MA | $0.74 | Dividend yield | N/A |
| 200-day MA | $3.08 | Market Cap | 1.73M |
BJDX Stock Price Chart Interactive Chart >
Bluejay Diagnostics, Inc. (BJDX) Company Bio
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Latest BJDX News From Around the Web
Below are the latest news stories about BLUEJAY DIAGNOSTICS INC that investors may wish to consider to help them evaluate BJDX as an investment opportunity.
Bluejay Diagnostics Announces Pricing of $3.5 Million Public OfferingACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a public offering of 2,692,308 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 p |
BJDX: SYMON Says: Start the Trial!By John Vandermosten, CFA NASDAQ:BJDX Bluejay Diagnostics, Inc. (NASDAQ:BJDX) issued a press release on December 27th, 2023 informing stakeholders that the clinical study evaluating the Symphony diagnostic in sepsis patients has started. The trial has been designated SYMON: Multicenter Sy mphony IL-6 Mon itoring Sepsis ICU Study. The study has been listed on the clinicaltrials.gov website under |
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), today announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients (the SYMON study). The Symphony System is designed to address the need for simple, reliable, rapid, near-patient testing |
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial ResultsACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2023. “Based on FDA’s feedback from the August 11, 2023, meeting, the Company focused on implementing the modifi |
BJDX: Toray License RenegotiationBy John Vandermosten, CFA NASDAQ:BJDX Bluejay Diagnostics, Inc. (NASDAQ:BJDX) has presented several pieces of material news in the last months adding a new CFO to its ranks, raising capital and renegotiating its license agreement with Toray Industries, Inc. Frances Scally was added as CFO of the company on September 26th following the former CFOs departure. The company raised gross proceeds of |
BJDX Price Returns
| 1-mo | N/A |
| 3-mo | -21.38% |
| 6-mo | -81.56% |
| 1-year | -89.29% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -47.54% |
| 2023 | -83.94% |
| 2022 | -85.16% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...